Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Updates on Anti-Cancer Drug Research
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Updates on Anti-Cancer Drug Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 410

Special Issue Editors

Dr. Ana Luísa De Sousa-Coelho

E-Mail Website
Guest Editor
1. Escola Superior de Saúde, Universidade do Algarve (ESSUAlg), Campus de Gambelas, 8005-139 Faro, Portugal 2. Algarve Biomedical Centre Research Institute (ABC-RI), Campus de Gambelas, 8005-139 Faro, Portugal
Interests: cancer metabolism; obesity; drug repurposing; biomarkers; personalized medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Mónica Fernandes

E-Mail Website
Guest Editor
1. Algarve Biomedical Center-Research Institute (ABC-RI), University of Algarve Campus Gambelas, 8005-139 Faro, Portugal
2. Escola Superior de Saúde, Universidade do Algarve (ESSUAlg), Campus de Gambelas, 8005-139 Faro, Portugal
Interests: biomarkers; cancer stemness; drug resistance; OMICS; personalized medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We announce a Special Issue dedicated to the latest advancements in anti-cancer drug research. As the understanding of cancer biology deepens, innovative approaches have become increasingly pivotal in identifying novel therapeutic targets, predicting drug responses, and overcoming resistance mechanisms.

This Special Issue will showcase cutting-edge research that enhances the development and efficacy of anti-cancer therapies. We invite researchers to submit original research articles and reviews that provide new insights into mechanistic studies, technological innovations, and clinical applications to refine cancer treatment strategies. This Special Issue will serve as a comprehensive resource for scientists and clinicians interested in integrating molecular biology and pharmacology to target and treat cancer more effectively.

Examples of anticipated, but non-exhaustive, submission topics are as follows:

  • Gene expression profiling in drug-resistant cancers;
  • Predictive biomarkers;
  • Impacts of epigenetic modifications on drug response;
  • Immune checkpoint inhibitors;
  • Novel computational approaches for analyzing gene expression in cancer;
  • Tumor microenvironments during therapy;
  • Pharmacogenomics and personalized medicine in cancer treatment.

Dr. Ana Luísa De Sousa-Coelho
Dr. Mónica Fernandes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anti-cancer drug research
  • drug resistance
  • biomarkers
  • pharmacogenomics
  • single-cell RNA sequencing
  • non-coding RNAs
  • multi-omics data

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

17 pages, 1749 KB  
Systematic Review
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis
by Ida Taglialatela, Beatrice Ruffilli, Benedetta Conte, Francesca D’Avanzo, Valentina Rossi, Simone Nardin and Alessandra Gennari
Cancers 2025, 17(24), 3961; https://doi.org/10.3390/cancers17243961 - 12 Dec 2025
Viewed by 220
Abstract
Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis and a high risk of early relapse. The incorporation of platinum-based agents into neoadjuvant chemotherapy (NACT) regimens has been linked to improved pathological complete response (pCR) rates. However, the clinical benefit of carboplatin [...] Read more.
Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis and a high risk of early relapse. The incorporation of platinum-based agents into neoadjuvant chemotherapy (NACT) regimens has been linked to improved pathological complete response (pCR) rates. However, the clinical benefit of carboplatin (CBDCA) remains debated due to variable long-term survival outcomes and concerns over cumulative toxicity. This meta-analysis evaluates the efficacy of adding CBDCA to NACT in early-stage TNBC (eTNBC). Methods: A systematic review and meta-analysis were conducted by searching MEDLINE, PubMed, and major oncology conference proceedings (2014–2024), with no language restrictions. Randomized phase II–III trials assessing the addition of CBDCA to standard NACT in eTNBC and reporting pCR and survival outcomes were included. The systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol has not been registered. The primary endpoint was pCR; the secondary endpoint was disease-free survival (DFS). For pCR, a random-effects model was used, and odds ratios (OR) were log-transformed. For DFS, a mixed-effects model was applied, extracting hazard ratios (HR) and converting them into logHR values. Heterogeneity was assessed using I2 statistics, and publication bias was evaluated through the Fail-Safe N method and Egger’s regression test. Statistical analyses were performed using Jamovi v2.4.11. Results: Of 30 studies identified, 9 randomized clinical trials were eligible; 6 (BrighTNess, GeparSixto, GS5-01, BR-15-1 PEARLY, NACATRINE, CALGB 40603) met all inclusion criteria, totaling 3402 patients. The addition of CBDCA to NACT significantly improved pCR (OR 1.63; 95% CI: 1.38–1.92; p < 0.001), with low heterogeneity (I2 = 0.81%) and no publication bias. DFS was also significantly improved (SHR 0.81; 95% CI: 0.63–0.91; p = 0.003), with moderate heterogeneity (I2 = 27.95%) and no bias detected. Conclusions: Adding carboplatin to NACT significantly improves pCR and DFS in patients with early-stage TNBC. Full article
(This article belongs to the Special Issue Updates on Anti-Cancer Drug Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop